Ubs Oconnor LLC Dyne Therapeutics, Inc. Transaction History
Ubs Oconnor LLC
- $1.46 Billion
- Q3 2024
A detailed history of Ubs Oconnor LLC transactions in Dyne Therapeutics, Inc. stock. As of the latest transaction made, Ubs Oconnor LLC holds 19,318 shares of DYN stock, worth $306,576. This represents 0.05% of its overall portfolio holdings.
Number of Shares
19,318Holding current value
$306,576% of portfolio
0.05%Shares
11 transactions
Others Institutions Holding DYN
# of Institutions
208Shares Held
102MCall Options Held
234KPut Options Held
238K-
Atlas Venture Life Science Advisors, LLC8.02MShares$127 Million35.54% of portfolio
-
Black Rock Inc. New York, NY7.39MShares$117 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.86MShares$109 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY6.82MShares$108 Million3.9% of portfolio
-
Janus Henderson Group PLC London, X06.81MShares$108 Million0.13% of portfolio
About Dyne Therapeutics, Inc.
- Ticker DYN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 51,765,400
- Market Cap $822M
- Description
- Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and...